spotlight: zolbetuximab and m-folfox6 in cldn18.2 , her2- gej cancer
Published 1 year ago • 777 plays • Length 2:49Download video MP4
Download video MP3
Similar videos
-
2:08
targeting cldn18.2 with zolbetuximab in gastric and gej cancer
-
1:52
iilustro: zolbetuximab, mfolfox6, and nivolumab combinations for gastrointestinal cancer
-
2:26
final os findings of zolbetuximab and folfox6 in the spotlight trial
-
1:35
assessing the prevalence of cldn18.2 in gastric/gastroesophageal cancers
-
2:17
claudin 18.2 and fgfr2b as novel targets in gastric cancer
-
1:44
what role will zolbetuximab play in treating gastric cancer?
-
2:56
will zolbetuximab impact the treatment landscape for gastric cancer?
-
3:34
flow spotlight: addressing nausea vomiting in gastric cancer treatment with 1l zolbetuximab
-
1:07
claudin 18.2: a biomarker for gastric cancer
-
0:51
claudin 18.2 as an emerging target in gastrointestinal cancers
-
2:09
recent advances in gastrointestinal research: destiny-gastric01 and spotlight
-
7:46
results from the phase 2 fast study of astellas’ investigational zolbetuximab
-
1:28
highlights in gastric and colorectal cancer at asco gi 2023
-
1:35
fight: bemarituzumab mfolfox6 in first-line advanced gastric cancer
-
3:03
targeted therapies for gastroesophageal adenocarcinoma
-
9:46
bemarituzumab mfolfox6 in first-line advanced gastric/gastroesophageal junction adenocarcinoma
-
8:41
fast: a phase iii trial of an anti-cldn18.2 antibody gej adenocarcinoma
-
1:04
dr. ilson on the utility of zolbetuximab in claudin-positive gastric cancers
-
0:58
lb1908: a novel car-t cell therapy targeting claudin 18.2 in gi malignancies